JP2023541457A5 - - Google Patents

Info

Publication number
JP2023541457A5
JP2023541457A5 JP2023516769A JP2023516769A JP2023541457A5 JP 2023541457 A5 JP2023541457 A5 JP 2023541457A5 JP 2023516769 A JP2023516769 A JP 2023516769A JP 2023516769 A JP2023516769 A JP 2023516769A JP 2023541457 A5 JP2023541457 A5 JP 2023541457A5
Authority
JP
Japan
Application number
JP2023516769A
Other languages
Japanese (ja)
Other versions
JPWO2022056489A5 (https=
JP2023541457A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/050328 external-priority patent/WO2022056489A1/en
Publication of JP2023541457A publication Critical patent/JP2023541457A/ja
Publication of JPWO2022056489A5 publication Critical patent/JPWO2022056489A5/ja
Publication of JP2023541457A5 publication Critical patent/JP2023541457A5/ja
Abandoned legal-status Critical Current

Links

JP2023516769A 2020-09-14 2021-09-14 Cd38修飾のための化合物および方法 Abandoned JP2023541457A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078035P 2020-09-14 2020-09-14
US63/078,035 2020-09-14
PCT/US2021/050328 WO2022056489A1 (en) 2020-09-14 2021-09-14 Compositions and methods for cd38 modification

Publications (3)

Publication Number Publication Date
JP2023541457A JP2023541457A (ja) 2023-10-02
JPWO2022056489A5 JPWO2022056489A5 (https=) 2024-09-26
JP2023541457A5 true JP2023541457A5 (https=) 2024-09-26

Family

ID=78080565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516769A Abandoned JP2023541457A (ja) 2020-09-14 2021-09-14 Cd38修飾のための化合物および方法

Country Status (4)

Country Link
US (1) US20230398219A1 (https=)
EP (1) EP4211244A1 (https=)
JP (1) JP2023541457A (https=)
WO (1) WO2022056489A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
KR20240017367A (ko) * 2021-06-02 2024-02-07 메타지노미, 인크. 클래스 ii, v형 crispr 시스템
EP4426338A2 (en) * 2021-11-03 2024-09-11 Intellia Therapeutics, Inc. Cd38 compositions and methods for immunotherapy
US20250295695A1 (en) * 2022-04-04 2025-09-25 Vor Biopharma Inc. Compositions and methods for mediating epitope engineering
CN119546757A (zh) 2022-05-25 2025-02-28 宏基因组学公司 肝酶表达的补充
KR20260036568A (ko) * 2023-07-10 2026-03-17 카스젠 라이프 사이언스 씨오., 엘티디. 세포 면역 요법용 조성물, 및 방법
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
EP3556858A3 (en) 2014-04-09 2020-01-22 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
US10900034B2 (en) 2014-12-03 2021-01-26 Agilent Technologies, Inc. Guide RNA with chemical modifications
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
EP3280803B1 (en) 2015-04-06 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
CN108290939B (zh) 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したCas9蛋白質
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
AU2017388753A1 (en) 2016-12-30 2019-07-11 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
SG11201907870VA (en) 2017-02-28 2019-09-27 Vor Biopharma Inc Compositions and methods for inhibition of lineage specific proteins
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11718659B2 (en) 2017-08-28 2023-08-08 The Trustees Of Columbia University In The City Of New York CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents
CN111918877A (zh) 2018-03-14 2020-11-10 美国卫生和人力服务部 抗cd33嵌合抗原受体及其用途
JP7575271B2 (ja) * 2018-03-29 2024-10-29 フェイト セラピューティクス,インコーポレイテッド 操作された免疫エフェクター細胞およびその使用
CA3110837A1 (en) * 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
CA3144356A1 (en) * 2019-06-21 2020-12-24 Function Oncology, Inc. A genetic pharmacopeia for comprehensive functional profiling of human cancers

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)